NCT00005652已完成2 期
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
研究概览
简要总结
OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura.
II. Evaluate the toxicity associated with this treatment regimen in these patients.
III. Evaluate the alteration in antiplatelet antibody with this treatment regimen in these patients.
详细描述
PROTOCOL OUTLINE: Patients receive rituximab IV on days 1, 8, 15, and 22. Patients who achieve a clinical response lasting over 4 months may receive a second course of rituximab.
Patients are followed at 5, 6, 8, and 12 weeks, and then at 6 and 9 months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia AHemophilia ANCT00306670Georgetown University2
已完成
不适用
Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20Multiple myeloma expressing CD20JPRN-UMIN000000531Zenyaku Kogyo Co., Ltd.39
终止
2 期
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00250861US Oncology Research110
招募中
2 期
Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety StudyAdvanced Hepatocellular CarcinomaNCT06301399Tianjin Medical University Cancer Institute and Hospital20
已完成
2 期
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic LeukemiaB-Chronic Lymphocytic LeukemiaNCT00201721Ohio State University Comprehensive Cancer Center28